Flucelvax 70461-0656
Generic: Influenza A Virus A/tasmania/318/2025 Cvr-351 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/tasmania/787/2025 Cvr-388 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/arizona/21/2025 Antigen (mdck Cell Derived, Propiolactone Inactivated)
Product NDC
70461-0656- Manufacturer
- Seqirus Inc.
- Dosage Form
- Injection, Suspension
- Route
- Intramuscular
- Product Type
- Vaccine
- Marketing Start
- July 1, 2026
- Application
- BLA125408
Active Ingredients
| Ingredient | Strength |
|---|---|
| Influenza A Virus A/tasmania/318/2025 Cvr-351 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated) | 15 ug/.5mL |
| Influenza A Virus A/tasmania/787/2025 Cvr-388 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated) | 15 ug/.5mL |
| Influenza B Virus - B/arizona/21/2025 Antigen (mdck Cell Derived, Propiolactone Inactivated) | 15 ug/.5mL |
Packaging Options(1)
10 SYRINGE, GLASS in 1 CARTON (70461-656-03) / .5 mL in 1 SYRINGE, GLASS (70461-656-04)
External Resources